Search research articles
Contact Us
Filters
Showing results (1-10 of 10) with videos related to
Page
of 1
Sort By:
Advanced Materials (Deerfield Beach, Fla.)
|
February 4, 2016
DNA Origami: Folded DNA-Nanodevices That Can Direct and Interpret Cell Behavior
Cathal J Kearney, Christopher R Lucas, Fergal J O'Brien, et al.
Molecular Nutrition & Food Research
|
August 7, 2018
Cruciferous Vegetables, Isothiocyanates, and Bladder Cancer Prevention
Besma Abbaoui, Christopher R Lucas, Ken M Riedl, et al.
ACS Nano
|
July 1, 2016
Probing Nucleosome Stability with a DNA Origami Nanocaliper
Jenny V Le, Yi Luo, Michael A Darcy, et al.
ACS Applied Materials & Interfaces
|
December 12, 2022
Multiplexed Detection of Molecular Interactions with DNA Origami Engineered Cells in 3D Collagen Matrices
Melika Shahhosseini, Peter E Beshay, Ehsan Akbari, et al.
Advanced Materials (Deerfield Beach, Fla.)
|
October 14, 2017
Engineering Cell Surface Function with DNA Origami
Ehsan Akbari, Molly Y Mollica, Christopher R Lucas, et al.
Journal of Proteomics
|
January 31, 2017
The impact of cruciferous vegetable isothiocyanates on histone acetylation and histone phosphorylation in bladder cancer
Besma Abbaoui, Kelly H Telu, Christopher R Lucas, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
December 18, 2012
Prohibitins and the cytoplasmic domain of CD86 cooperate to mediate CD86 signaling in B lymphocytes
Christopher R Lucas, Hector M Cordero-Nieves, Robert S Erbe, et al.
Small (Weinheim an Der Bergstrasse, Germany)
|
November 20, 2015
Daunorubicin-Loaded DNA Origami Nanostructures Circumvent Drug-Resistance Mechanisms in a Leukemia Model
Patrick D Halley, Christopher R Lucas, Emily M McWilliams, et al.
Small (Weinheim an Der Bergstrasse, Germany)
|
May 28, 2022
DNA Origami Nanostructures Elicit Dose-Dependent Immunogenicity and Are Nontoxic up to High Doses In Vivo
Christopher R Lucas, Patrick D Halley, Amjad A Chowdury, et al.
Blood Advances
|
February 10, 2019
Anti-BAFF-R antibody VAY-736 demonstrates promising preclinical activity in CLL and enhances effectiveness of ibrutinib
Emily M McWilliams, Christopher R Lucas, Timothy Chen, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 10) with videos related to
Sort By:
Page
of 1
Advanced Materials (Deerfield Beach, Fla.)
|
February 4, 2016
DNA Origami: Folded DNA-Nanodevices That Can Direct and Interpret Cell Behavior
Cathal J Kearney, Christopher R Lucas, Fergal J O'Brien, et al.
Molecular Nutrition & Food Research
|
August 7, 2018
Cruciferous Vegetables, Isothiocyanates, and Bladder Cancer Prevention
Besma Abbaoui, Christopher R Lucas, Ken M Riedl, et al.
ACS Nano
|
July 1, 2016
Probing Nucleosome Stability with a DNA Origami Nanocaliper
Jenny V Le, Yi Luo, Michael A Darcy, et al.
ACS Applied Materials & Interfaces
|
December 12, 2022
Multiplexed Detection of Molecular Interactions with DNA Origami Engineered Cells in 3D Collagen Matrices
Melika Shahhosseini, Peter E Beshay, Ehsan Akbari, et al.
Advanced Materials (Deerfield Beach, Fla.)
|
October 14, 2017
Engineering Cell Surface Function with DNA Origami
Ehsan Akbari, Molly Y Mollica, Christopher R Lucas, et al.
Journal of Proteomics
|
January 31, 2017
The impact of cruciferous vegetable isothiocyanates on histone acetylation and histone phosphorylation in bladder cancer
Besma Abbaoui, Kelly H Telu, Christopher R Lucas, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
December 18, 2012
Prohibitins and the cytoplasmic domain of CD86 cooperate to mediate CD86 signaling in B lymphocytes
Christopher R Lucas, Hector M Cordero-Nieves, Robert S Erbe, et al.
Small (Weinheim an Der Bergstrasse, Germany)
|
November 20, 2015
Daunorubicin-Loaded DNA Origami Nanostructures Circumvent Drug-Resistance Mechanisms in a Leukemia Model
Patrick D Halley, Christopher R Lucas, Emily M McWilliams, et al.
Small (Weinheim an Der Bergstrasse, Germany)
|
May 28, 2022
DNA Origami Nanostructures Elicit Dose-Dependent Immunogenicity and Are Nontoxic up to High Doses In Vivo
Christopher R Lucas, Patrick D Halley, Amjad A Chowdury, et al.
Blood Advances
|
February 10, 2019
Anti-BAFF-R antibody VAY-736 demonstrates promising preclinical activity in CLL and enhances effectiveness of ibrutinib
Emily M McWilliams, Christopher R Lucas, Timothy Chen, et al.
Page
of 1